Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 329

1.

The influence of ketamine on drug discovery in depression.

Kraus C, Wasserman D, Henter ID, Acevedo-Diaz E, Kadriu B, Zarate CA Jr.

Drug Discov Today. 2019 Aug 2. pii: S1359-6446(19)30283-1. doi: 10.1016/j.drudis.2019.07.007. [Epub ahead of print] Review.

PMID:
31382015
2.

Multimodal imaging reveals a complex pattern of dysfunction in corticolimbic pathways in major depressive disorder.

Nugent AC, Farmer C, Evans JW, Snider SL, Banerjee D, Zarate CA Jr.

Hum Brain Mapp. 2019 Sep;40(13):3940-3950. doi: 10.1002/hbm.24679. Epub 2019 Jun 9.

PMID:
31179620
3.

Correction to: Mapping anticipatory anhedonia: an fMRI study.

Szczepanik JE, Reed JL, Nugent AC, Ballard ED, Evans JW, Lejuez CW, Zarate CA Jr.

Brain Imaging Behav. 2019 Jun 6. doi: 10.1007/s11682-019-00131-6. [Epub ahead of print]

PMID:
31172359
4.

Depression in the Primary Care Setting. Reply.

Park LT, Zarate CA Jr.

N Engl J Med. 2019 Jun 6;380(23):2279-2280. doi: 10.1056/NEJMc1903259. No abstract available.

5.

Mapping anticipatory anhedonia: an fMRI study.

Szczepanik JE, Reed JL, Nugent AC, Ballard ED, Evans JW, Lejuez CW, Zarate CA Jr.

Brain Imaging Behav. 2019 Apr 27. doi: 10.1007/s11682-019-00084-w. [Epub ahead of print] Erratum in: Brain Imaging Behav. 2019 Jun 6;:.

PMID:
31030316
6.

Prognosis and improved outcomes in major depression: a review.

Kraus C, Kadriu B, Lanzenberger R, Zarate CA Jr, Kasper S.

Transl Psychiatry. 2019 Apr 3;9(1):127. doi: 10.1038/s41398-019-0460-3. Review.

7.

Familial Aggregation and Coaggregation of Suicide Attempts and Comorbid Mental Disorders in Adults.

Ballard ED, Cui L, Vandeleur C, Castelao E, Zarate CA Jr, Preisig M, Merikangas KR.

JAMA Psychiatry. 2019 Mar 27. doi: 10.1001/jamapsychiatry.2019.0248. [Epub ahead of print]

PMID:
30916728
8.

(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions.

Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, Morris PJ, Thomas CJ, Moaddel R, Zarate CA Jr, Gould TD.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6441-6450. doi: 10.1073/pnas.1819540116. Epub 2019 Mar 13.

9.

Correction: Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.

Guo W, Machado-Vieira R, Mathew S, Murrough JW, Charney DS, Grunebaum M, Oquendo MA, Kadriu B, Akula N, Henter I, Yuan P, Merikangas K, Drevets W, Furey M, Mann JJ, McMahon FJ, Zarate CA Jr, Shugart YY.

Transl Psychiatry. 2019 Mar 5;9(1):108. doi: 10.1038/s41398-019-0442-5.

10.

Effects of Ketamine on Brain Activity During Emotional Processing: Differential Findings in Depressed Versus Healthy Control Participants.

Reed JL, Nugent AC, Furey ML, Szczepanik JE, Evans JW, Zarate CA Jr.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2019 Jul;4(7):610-618. doi: 10.1016/j.bpsc.2019.01.005. Epub 2019 Jan 25.

PMID:
30826253
11.

Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function.

Lumsden EW, Troppoli TA, Myers SJ, Zanos P, Aracava Y, Kehr J, Lovett J, Kim S, Wang FH, Schmidt S, Jenne CE, Yuan P, Morris PJ, Thomas CJ, Zarate CA Jr, Moaddel R, Traynelis SF, Pereira EFR, Thompson SM, Albuquerque EX, Gould TD.

Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5160-5169. doi: 10.1073/pnas.1816071116. Epub 2019 Feb 22.

12.

Functional Imaging of the Implicit Association of the Self With Life and Death.

Ballard ED, Reed JL, Szczepanik J, Evans JW, Yarrington JS, Dickstein DP, Nock MK, Nugent AC, Zarate CA Jr.

Suicide Life Threat Behav. 2019 Feb 13. doi: 10.1111/sltb.12543. [Epub ahead of print]

PMID:
30761601
13.

Depression in the Primary Care Setting.

Park LT, Zarate CA Jr.

N Engl J Med. 2019 Feb 7;380(6):559-568. doi: 10.1056/NEJMcp1712493. Review. No abstract available.

14.

Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant.

Wilkinson ST, Farmer C, Ballard ED, Mathew SJ, Grunebaum MF, Murrough JW, Sos P, Wang G, Gueorguieva R, Zarate CA Jr.

Neuropsychopharmacology. 2019 Jun;44(7):1233-1238. doi: 10.1038/s41386-019-0317-8. Epub 2019 Jan 17.

PMID:
30653192
15.

Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.

Guo W, Machado-Vieira R, Mathew S, Murrough JW, Charney DS, Grunebaum M, Oquendo MA, Kadriu B, Akula N, Henter I, Yuan P, Merikangas K, Drevets W, Furey M, Mann JJ, McMahon FJ, Zarate CA Jr, Shugart YY.

Transl Psychiatry. 2018 Dec 14;8(1):280. doi: 10.1038/s41398-018-0311-7. Erratum in: Transl Psychiatry. 2019 Mar 5;9(1):108.

16.

Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.

Nugent AC, Wills KE, Gilbert JR, Zarate CA Jr.

Psychiatry Res Neuroimaging. 2019 Jan 30;283:64-66. doi: 10.1016/j.pscychresns.2018.09.001. Epub 2018 Sep 12.

17.

Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ( 2R,6R)-hydroxynorketamine.

Highland JN, Morris PJ, Zanos P, Lovett J, Ghosh S, Wang AQ, Zarate CA Jr, Thomas CJ, Moaddel R, Gould TD.

J Psychopharmacol. 2018 Nov 29:269881118812095. doi: 10.1177/0269881118812095. [Epub ahead of print]

PMID:
30488740
18.

Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.

Kadriu B, Musazzi L, Henter ID, Graves M, Popoli M, Zarate CA Jr.

Int J Neuropsychopharmacol. 2019 Feb 1;22(2):119-135. doi: 10.1093/ijnp/pyy094.

19.

Are 24-hour motor activity patterns associated with continued rapid response to ketamine?

Duncan WC Jr, Slonena EE, Hejazi NS, Brutsche N, Park LT, Henter ID, Ballard ED, Zarate CA Jr.

Neuropsychiatr Dis Treat. 2018 Oct 16;14:2739-2748. doi: 10.2147/NDT.S172089. eCollection 2018.

20.

Disentangling the association of depression on the anti-fatigue effects of ketamine.

Saligan LN, Farmer C, Ballard ED, Kadriu B, Zarate CA Jr.

J Affect Disord. 2019 Feb 1;244:42-45. doi: 10.1016/j.jad.2018.10.089. Epub 2018 Oct 6.

PMID:
30312839
21.

Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.

Gould TD, Zarate CA Jr, Thompson SM.

Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:213-236. doi: 10.1146/annurev-pharmtox-010617-052811. Epub 2018 Oct 8.

22.

Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.

Park L, Furey M, Nugent AC, Farmer C, Ellis J, Szczepanik J, Lener MS, Zarate CA Jr.

Int J Neuropsychopharmacol. 2019 Jan 1;22(1):10-18. doi: 10.1093/ijnp/pyy051.

23.

Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.

Moaddel R, Shardell M, Khadeer M, Lovett J, Kadriu B, Ravichandran S, Morris PJ, Yuan P, Thomas CJ, Gould TD, Ferrucci L, Zarate CA.

Psychopharmacology (Berl). 2018 Oct;235(10):3017-3030. doi: 10.1007/s00213-018-4992-7. Epub 2018 Aug 16.

24.

Characterizing the course of suicidal ideation response to ketamine.

Ballard ED, Yarrington JS, Farmer CA, Richards E, Machado-Vieira R, Kadriu B, Niciu MJ, Yuan P, Park L, Zarate CA Jr.

J Affect Disord. 2018 Dec 1;241:86-93. doi: 10.1016/j.jad.2018.07.077. Epub 2018 Jul 30.

25.

Ketamine normalizes brain activity during emotionally valenced attentional processing in depression.

Reed JL, Nugent AC, Furey ML, Szczepanik JE, Evans JW, Zarate CA Jr.

Neuroimage Clin. 2018 Jul 5;20:92-101. doi: 10.1016/j.nicl.2018.07.006. eCollection 2018.

26.

PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects.

Richards EM, Zanotti-Fregonara P, Fujita M, Newman L, Farmer C, Ballard ED, Machado-Vieira R, Yuan P, Niciu MJ, Lyoo CH, Henter ID, Salvadore G, Drevets WC, Kolb H, Innis RB, Zarate CA Jr.

EJNMMI Res. 2018 Jul 3;8(1):57. doi: 10.1186/s13550-018-0401-9.

27.

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD.

Pharmacol Rev. 2018 Jul;70(3):621-660. doi: 10.1124/pr.117.015198. Review. Erratum in: Pharmacol Rev. 2018 Oct;70(4):879.

28.

7T 1H-MRS in major depressive disorder: a Ketamine Treatment Study.

Evans JW, Lally N, An L, Li N, Nugent AC, Banerjee D, Snider SL, Shen J, Roiser JP, Zarate CA Jr.

Neuropsychopharmacology. 2018 Aug;43(9):1908-1914. doi: 10.1038/s41386-018-0057-1. Epub 2018 Apr 5.

29.

Preventing suicide: A multicausal model requires multimodal research and intervention.

Ballard ED, Zarate CA Jr.

Bipolar Disord. 2018 Sep;20(6):558-559. doi: 10.1111/bdi.12656. Epub 2018 May 5. No abstract available.

30.

Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.

Gilbert JR, Yarrington JS, Wills KE, Nugent AC, Zarate CA Jr.

Int J Neuropsychopharmacol. 2018 Apr 13. doi: 10.1093/ijnp/pyy041. [Epub ahead of print]

31.

Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability.

Kadriu B, Yuan S, Farmer C, Nugent AC, Lener MS, Niciu MJ, Park M, Yazdian A, Ballard ED, Henn FA, Henter ID, Park LT, Zarate CA Jr.

J Clin Psychopharmacol. 2018 Jun;38(3):243-246. doi: 10.1097/JCP.0000000000000866.

32.

Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration.

Evans JW, Szczepanik J, Brutsché N, Park LT, Nugent AC, Zarate CA Jr.

Biol Psychiatry. 2018 Oct 15;84(8):582-590. doi: 10.1016/j.biopsych.2018.01.027. Epub 2018 Feb 15.

33.

Using Neuroimaging to Decipher the Mechanism of Action of Ketamine: A Pathway to Novel Therapeutics?

Nugent AC, Zarate CA Jr.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Oct;2(7):549-551. doi: 10.1016/j.bpsc.2017.08.006. Epub 2017 Oct 5. No abstract available.

34.

Convergent Mechanisms Underlying Rapid Antidepressant Action.

Zanos P, Thompson SM, Duman RS, Zarate CA Jr, Gould TD.

CNS Drugs. 2018 Mar;32(3):197-227. doi: 10.1007/s40263-018-0492-x. Review.

35.

Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.

Niciu MJ, Shovestul BJ, Jaso BA, Farmer C, Luckenbaugh DA, Brutsche NE, Park LT, Ballard ED, Zarate CA Jr.

J Affect Disord. 2018 May;232:310-315. doi: 10.1016/j.jad.2018.02.049. Epub 2018 Feb 17.

36.

The development of glutamate-based antidepressants is taking longer than expected.

Garay R, Zarate CA Jr, Cavero I, Kim YK, Charpeaud T, Skolnick P.

Drug Discov Today. 2018 Oct;23(10):1689-1692. doi: 10.1016/j.drudis.2018.02.006. Epub 2018 Mar 1. No abstract available.

37.

Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.

Nugent AC, Ballard ED, Gould TD, Park LT, Moaddel R, Brutsche NE, Zarate CA Jr.

Mol Psychiatry. 2019 Jul;24(7):1040-1052. doi: 10.1038/s41380-018-0028-2. Epub 2018 Feb 27.

38.

Glutamatergic Modulators in Depression.

Henter ID, de Sousa RT, Zarate CA Jr.

Harv Rev Psychiatry. 2018 Nov/Dec;26(6):307-319. doi: 10.1097/HRP.0000000000000183. Review.

PMID:
29465478
39.

Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales.

Ballard ED, Yarrington JS, Farmer CA, Lener MS, Kadriu B, Lally N, Williams D, Machado-Vieira R, Niciu MJ, Park L, Zarate CA Jr.

J Affect Disord. 2018 Apr 15;231:51-57. doi: 10.1016/j.jad.2018.01.027. Epub 2018 Feb 5.

40.

daTALbase: A Database for Genomic and Transcriptomic Data Related to TAL Effectors.

PĂ©rez-Quintero AL, Lamy L, Zarate CA, Cunnac S, Doyle E, Bogdanove A, Szurek B, Dereeper A.

Mol Plant Microbe Interact. 2018 Apr;31(4):471-480. doi: 10.1094/MPMI-06-17-0153-FI. Epub 2018 Feb 14.

PMID:
29143556
41.

The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder.

Niciu MJ, Iadarola ND, Banerjee D, Luckenbaugh DA, Park M, Lener M, Park L, Ionescu DF, Ballard ED, Brutsche NE, Akula N, McMahon FJ, Machado-Vieira R, Nugent AC, Zarate CA Jr.

J Psychopharmacol. 2017 Dec;31(12):1570-1577. doi: 10.1177/0269881117732514. Epub 2017 Oct 17.

42.

The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.

Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA Jr, Sanacora G.

Am J Psychiatry. 2018 Feb 1;175(2):150-158. doi: 10.1176/appi.ajp.2017.17040472. Epub 2017 Oct 3. Review.

43.

Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood.

Duncan WC Jr, Ballard ED, Zarate CA.

Handb Exp Pharmacol. 2019;253:337-358. doi: 10.1007/164_2017_51.

44.

What Should be Done When Elderly Patients with Major Depression Have Failed to Respond to All Treatments?

Zarate CA Jr.

Am J Geriatr Psychiatry. 2017 Nov;25(11):1210-1212. doi: 10.1016/j.jagp.2017.08.009. Epub 2017 Aug 30. No abstract available.

45.

Correction to "Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites".

Morris PJ, Moaddel R, Zanos P, Moore CE, Gould TD, Zarate CA Jr, Thomas CJ.

Org Lett. 2017 Oct 6;19(19):5494. doi: 10.1021/acs.orglett.7b02839. Epub 2017 Sep 21. No abstract available.

PMID:
28933164
46.

Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites.

Morris PJ, Moaddel R, Zanos P, Moore CE, Gould TD, Zarate CA Jr, Thomas CJ.

Org Lett. 2017 Sep 1;19(17):4572-4575. doi: 10.1021/acs.orglett.7b02177. Epub 2017 Aug 22. Erratum in: Org Lett. 2017 Oct 6;19(19):5494.

47.

Altered interaction with environmental reinforcers in major depressive disorder: Relationship to anhedonia.

Szczepanik JE, Furey ML, Nugent AC, Henter ID, Zarate CA Jr, Lejuez CW.

Behav Res Ther. 2017 Oct;97:170-177. doi: 10.1016/j.brat.2017.08.003. Epub 2017 Aug 3.

48.

Active suicidal ideation during clinical antidepressant trials.

Ballard ED, Snider SL, Nugent AC, Luckenbaugh DA, Park L, Zarate CA Jr.

Psychiatry Res. 2017 Nov;257:303-308. doi: 10.1016/j.psychres.2017.07.065. Epub 2017 Jul 31.

49.

Zanos et al. reply.

Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KSS, Fang Y, Huang XP, Mayo CL, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA, Gould TD.

Nature. 2017 Jun 21;546(7659):E4-E5. doi: 10.1038/nature22085. No abstract available.

50.

Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder.

Kadriu B, Gold PW, Luckenbaugh DA, Lener MS, Ballard ED, Niciu MJ, Henter ID, Park LT, De Sousa RT, Yuan P, Machado-Vieira R, Zarate CA.

Mol Psychiatry. 2018 Jul;23(7):1626-1631. doi: 10.1038/mp.2017.109. Epub 2017 May 30.

Supplemental Content

Loading ...
Support Center